June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Topical Bromfenac 0.1% suppresses Concanavalin-A Induced Blood Retinal Barrier Breakdown
Author Affiliations & Notes
  • Hiroaki Takahashi
    Research Laboratory for Drug Development, Senju Pharmaceutical Co, Ltd, Kobe, Japan
  • Tetsuo Kida
    Research Laboratory for Drug Development, Senju Pharmaceutical Co, Ltd, Kobe, Japan
  • Seiko Kozai
    Research Laboratory for Drug Development, Senju Pharmaceutical Co, Ltd, Kobe, Japan
  • Hideki Tokushige
    Research Laboratory for Drug Development, Senju Pharmaceutical Co, Ltd, Kobe, Japan
  • Footnotes
    Commercial Relationships Hiroaki Takahashi, Senju Pharmaceutical Co, Ltd (E); Tetsuo Kida, Senju Pharmaceutical Co., Ltd. (E); Seiko Kozai, Senju Pharmaceutical Co, Ltd (E); Hideki Tokushige, Senju Pharmaceutical Co., Ltd. (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 6363. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hiroaki Takahashi, Tetsuo Kida, Seiko Kozai, Hideki Tokushige; Topical Bromfenac 0.1% suppresses Concanavalin-A Induced Blood Retinal Barrier Breakdown. Invest. Ophthalmol. Vis. Sci. 2013;54(15):6363.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the inhibitory effect of topically applied bromfenac sodium (BF) 0.1% ophthalmic solution, a non-steroidal anti-inflammatory drug (NSAID) possessing potent cyclooxygenase (COX)-1 and COX-2 inhibitory activity, in rabbit with blood-retinal barrier (BRB) breakdown induced by intravitreally administered Concanavalin A (ConA), and also to compare the effect of BF 0.1% with other ophthalmic NSAIDs, nepafenac (NF) 0.1% and diclofenac (DF) sodium 0.1%, in this model.

Methods: Male Dutch-belted rabbits (2.0-2.5 kg) were used. ConA (5 μg/eye) or vehicle (sterile saline) was injected intravitreally to unilateral eye of the anesthetized rabbits. Rabbits were topically applied with 50 μL of BF 0.1%, NF 0.1% or DF 0.1% three times a day on days -1, 0, 1, 2 relative to ConA injection (day 0). Three days after ConA injection, rabbits were euthanized and the vitreous bodies were isolated. The protein concentration in the vitreous body was measured by BCA methods to assess BRB breakdown.

Results: The vitreous protein concentrations in ConA -injected rabbits was 2117 ± 400 μg/mL (mean ± SD, n=6), and significantly increased compared with that in vehicle-injected rabbits (1307 ± 501 μg/mL (n=6)). The vitreous protein concentrations of BF 0.1%, NF 0.1%, and DF 0.1% groups were 1474 ± 574 (n=6), 1674 ± 452 (n=6), and 1800 ± 351 (n=7) μg/mL respectively. BF 0.1% significantly suppressed BRB breakdown in this model (p<0.05, Dunnett multiple comparisons test, one-side). However, NF 0.1% and DF 0.1% did not significantly suppress in this study.

Conclusions: Topical BF 0.1% was more potent than topical NF 01% and DF 0.1% in the ConA-induced BRB breakdown model. Therefore, it is suggested that topical BF 0.1% may have a therapeutical potential to retinal edema resulting from BRB breakdown induced by inflammation.

Keywords: 688 retina • 505 edema • 503 drug toxicity/drug effects  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×